Presentation is loading. Please wait.

Presentation is loading. Please wait.

Presenter Disclosure Information DISCLOSURE INFORMATION The following relationships exist related to this presentation: WEARIT-II was supported by ZOLL.

Similar presentations


Presentation on theme: "Presenter Disclosure Information DISCLOSURE INFORMATION The following relationships exist related to this presentation: WEARIT-II was supported by ZOLL."— Presentation transcript:

1 Presenter Disclosure Information DISCLOSURE INFORMATION The following relationships exist related to this presentation: WEARIT-II was supported by ZOLL. Valentina Kutyifa, MD, PhD Results From The Prospective Registry Of Patients Using The Wearable Defibrillator (WEARIT-II Registry)

2 Valentina, Kutyifa, MD, PhD, Ilan Goldenberg, MD, Wojciech Zareba, MD, PhD, Helmut Klein, MD, Chingping Wan, MD, Bonnie MacKecknie, Mark L. Andrews, MS, Steve Szymkiewicz, MD and Arthur J. Moss, MD From the Cardiology Division of the Department of Medicine (VK, IG, WZ, HK, BM, MLA, AJM), University of Rochester Medical Center, Rochester, N.Y.; Sheba Medical Center and Tel Aviv University, Israel (IG); and ZOLL, Pittsburgh, PA (SS, CW)

3 BACKGROUND: CURRENT GUIDELINES FOR PRIMARY ICD THERAPY EF ≤ 35%EF ≤ 35% High-risk inherited arrhythmiasHigh-risk inherited arrhythmias AHA/ACC/HRS 2012 Guidelines 0.64

4 BACKGROUND: NEED FOR IMPROVED SELECTION OF PATIENTS FOR PRIMARY ICD THERAPY l MADIT-II:  Only one third of pts received appropriate ICD therapy over 4 years of FU Moss et al. NEJM 2002 l MADIT-RIT:  ICD programing to <200 bpm is associated with increased risk for inappropriate Rx and mortality  Rate of appropriate ICD shocks was only 4% (event rate: 3 appr. ICD shocks per 100 pt-yrs) Moss et al. NEJM 2012

5 LIFEVEST WEARABLE CARDIOVERTER DEFIBRILLATOR (WCD) l Can be used to bridge a decision for appropriate ICD therapy in:  Post-MI pts  Following coronary revascularization  New onset dilated (non-ischemic) CMP  High risk patients until stabilization  Inherited arrhythmic or congenital disorders l Availability of response button can be used to reduce inappropriate Rx

6 STUDY PURPOSE l To provide prospective data on the safety and efficacy of a bridging strategy with the WCD in a real world setting

7 WEARIT-II: REGISTRY DESIGN WCD (LifeVest) prescription in the US Informed consent Acquisition of baseline clinical data Wearing time: 3 months Clinical and Arrhythmic event acquisition WCD return: end of use evaluation 12 month FU

8 STUDY POPULATION l l N= 2000 patients enrolled in the US ä ä Currently enrolling patients in Europe, Israel l l Study duration: August 2011 – December 2013 l l Data management: University of Rochester l l Ischemic cardiomyopathy805 pts, 40.3% l l Non-ischemic CMP927 pts, 46.4% l l Cong/inherited268 pts, 13.4%

9 CONGENITAL, INHERITED HEART DISEASE l Initial diagnosis at baseline (n=268, 13.4%) * Allows for multiple diagnoses.

10 CHARACTERISTICS OF PATIENTS All Patients N=2000 Ischemic N=805 Non-ischemic N=927 Cong/Inherited N=268 Age, yrs (median) †59* Female 30%23%36%†30%* EF (median) 25%30%25% †25% * HF symptoms 52%48%52%63%* Diabetes 28%35%21%†30%* Prior ACA 9%11%7%†7% * p-value < 0.05 ischemic, non-ischemic, cong/inherited, † p-value < 0.05 ischemic, non-ischemic Data are reported by patients using a baseline evaluation form.

11 ARRHYTHMIC EVENTS: TOTAL POPULATION (WEAR DAYS MEDIAN 90 days) Patients (%) Events (events/pt) Event Rate Per 100 Pt- Year Any VT/VF * 41 (2.1%)120 (2.9)22 NSVT 28 (1.4%)164 (5.9)30 Atrial arrhythmias/SVT 72 (3.6%)561 (7.8)121 Asystole 6 (0.3%)9 (1.5)2 *Treated VT/VF and those VT’s that were spontaneously terminated, response button use or extended detection time.

12 ARRHYTHMIC EVENTS: WEARIT-II VS. MADIT-RIT MADIT-RIT Arms B&CWEARIT-II

13 ANY VT/VF BY DISEASE ETIOLOGY

14 SAFETY END POINTS TYPE TOTAL N=2000 Inappropriate Rx, n (%)10 (0.5%) Death, n (%) with the WCD 3 (0.2%)* * WCD detected asystole at the time of death No death related to unsuccessful termination of VT/VF 12-m FU data on death are still being collected

15 l Daily wear hours: median 22.5 hours COMPLIANCE

16 COMPLIANCE BY DISEASE ETIOLOGY

17 END OF USE BY ETIOLOGY

18 DETECTED WCD ARRHYTHMIAS AND END OF USE DECISION

19 CONCLUSIONS l In a real world setting a management strategy that incorporates the WCD can be safely used to bridge a decision for appropriate ICD therapy in patients with acquired, inherited, and congenital, heart disease:  Safe termination of life-threatening arrhythmic events  Low rate of inappropriate therapies  Risk assessment tool to identify patients at higher risk for SCD who need subsequent ICD implantation

20 Thank You


Download ppt "Presenter Disclosure Information DISCLOSURE INFORMATION The following relationships exist related to this presentation: WEARIT-II was supported by ZOLL."

Similar presentations


Ads by Google